– USA, TX – Aspira Women’s Health Inc. (NASDAQ: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced the appointments of Dr. Bob Auerbach and Ruby Sharma to its Board of Directors.
“We warmly welcome both Bob and Ruby to our Board. Each brings different – but equally critical – skills and expertise to the board. Bob’s medical background and track record of success as an executive in the women’s health sector along with Ruby’s strategic mindset and extensive financial, business and governance acumen will be highly valuable to Aspira as we accelerate our strategic execution in today’s challenging environment,” said CEO, Nicole Sandford.
About Dr. Robert Auerbach
Dr. Bob Auerbach retired President of CooperSurgical Inc., brings extensive experience in the medical industry, including experience as a director and as an executive officer. Ms. Sharma, the Managing Partner at RNB Strategic Advisors, brings decades of senior leadership, accounting, and audit committee experience.
Dr. Bob Auerbach retired in 2020 as President of CooperSurgical Inc., a wholly-owned subsidiary of CooperCompanies. Having joined CooperSurgical in 2005, Dr. Auerbach previously held EVP positions, including CMO and CSO. Dr. Auerbach continues to serve as an adjunct faculty member and as an Executive Board Member of the Center for Biomedical Innovation and Technology at Yale University and has also been a member of the Yale School of Medicine clinical faculty. He currently serves on the Board of Directors of OCON Healthcare, Escala Medical, Empress Medical, and AblaCare, as well as an advisor to CooperSurgical and GestVision.
He is a graduate of the Lehigh-Hahnemann 6-year BA-MD program and completed his OB/GYN residency at Yale.
About Ruby Sharma
Ruby Sharma, a seasoned professional and qualified audit committee financial expert, is a Managing Partner at RNB Strategic Advisors. Ruby serves as a member of the board of directors of Nautilus, Inc. (NYSE: NLS) and ShotSpotter, Inc. (NASDAQ: SSTI) and previously served as a Trustee and chair of the audit committee at Penn Medicine Princeton Health. Ruby retired in 2017 as Senior Partner from Ernst & Young LLP and has also held senior management positions with Arthur Andersen, LLP, and Grant Thornton GmbH.
Ms. Sharma is a Fellow Chartered Accountant and holds a B. A. in Economics from Delhi University, India. Ms. Sharma has also attended the Executive Education program for EY Partners at Northwestern University, Kellogg School of Management.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus combines our FDA-cleared products, OVA1 and OVERA, to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is working to deliver a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development include OVAWatch and EndoCheck. To improve patient accessibility, Aspira Women’s Health has recently launched our Aspira Synergy technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house.
For more information: https://aspirawh.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
